

# Resource Summary Report

Generated by ASWG on Aug 9, 2026

## CD140b Antibody, anti-human, PE, REAfinity™

RRID:AB\_2819521

Type: Antibody

### Proper Citation

Miltenyi Biotec Cat# 130-123-772, RRID:AB\_2819521

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2819521](http://antibodyregistry.org/AB_2819521)

**Proper Citation:** Miltenyi Biotec Cat# 130-123-772, RRID:AB\_2819521

**Target Antigen:** CD140b

**Host Organism:** human

**Clonality:** monoclonal

**Antibody Name:** CD140b Antibody, anti-human, PE, REAfinity™

**Description:** This monoclonal targets CD140b

**Target Organism:** human

**Clone ID:** clone REA363

**Antibody ID:** AB\_2819521

**Vendor:** Miltenyi Biotec

**Catalog Number:** 130-123-772

**Record Creation Time:** 20250819T235119+0000

**Record Last Update:** 20250820T063740+0000

### Ratings and Alerts

No rating or validation information has been found for CD140b Antibody, anti-human, PE, REAfinity™.

No alerts have been found for CD140b Antibody, anti-human, PE, REAfinity™.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 1 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [ASWG](#) .

Kirkeby A, et al. (2023) Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson's disease, STEM-PD. Cell stem cell, 30(10), 1299.